Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease
- PMID: 12373519
- DOI: 10.1007/s00726-001-0110-x
Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease
Abstract
Despite its being the most efficacious drug for symptom reversal in Parkinson's disease (PD), there is concern that chronic levodopa (L-DOPA) treatment may be detrimental. In this paper we review the potential for L-DOPA to 1). autoxidize from a catechol to a quinone, and 2). generate other reactive oxygen species (ROS). Overt toxicity and neuroprotective effects of L-DOPA, both in vivo and in vitro, are described in the context of whether L-DOPA may accelerate or delay progression of human Parkinson's disease.
Similar articles
-
Peculiarities of L: -DOPA treatment of Parkinson's disease.Amino Acids. 2005 Mar;28(2):157-64. doi: 10.1007/s00726-005-0162-4. Epub 2005 Mar 9. Amino Acids. 2005. PMID: 15750845 Review.
-
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?Prog Neurobiol. 2011 Sep 1;94(4):389-407. doi: 10.1016/j.pneurobio.2011.06.005. Epub 2011 Jun 24. Prog Neurobiol. 2011. PMID: 21723913 Review.
-
Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa.J Neurochem. 2006 Aug;98(4):1061-7. doi: 10.1111/j.1471-4159.2006.03941.x. Epub 2006 Jun 12. J Neurochem. 2006. PMID: 16771833
-
Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.J Neurochem. 2009 Nov;111(4):1042-50. doi: 10.1111/j.1471-4159.2009.06381.x. Epub 2009 Sep 16. J Neurochem. 2009. PMID: 19765187
-
Levodopa in the early treatment of Parkinson's disease.Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S17-20. doi: 10.1016/S1353-8020(09)70006-9. Parkinsonism Relat Disord. 2009. PMID: 19131036 Review.
Cited by
-
Pharmacological, Biochemical and Immunological Studies on Protective Effect of Mangiferin in 6-Hydroxydopamine (6-OHDA)-Induced Parkinson's Disease in Rats.Ann Neurosci. 2021 Jul;28(3-4):137-149. doi: 10.1177/09727531211051976. Epub 2021 Nov 2. Ann Neurosci. 2021. PMID: 35341236 Free PMC article.
-
Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats.Neurotox Res. 2004;5(8):569-77. doi: 10.1007/BF03033177. Neurotox Res. 2004. PMID: 15111234
-
Therapeutic effects of fucoidan in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: Role of NADPH oxidase-1.CNS Neurosci Ther. 2014 Dec;20(12):1036-44. doi: 10.1111/cns.12340. Epub 2014 Nov 15. CNS Neurosci Ther. 2014. PMID: 25399812 Free PMC article.
-
Microglial responses to dopamine in a cell culture model of Parkinson's disease.Neurobiol Aging. 2009 Nov;30(11):1805-17. doi: 10.1016/j.neurobiolaging.2008.01.001. Epub 2008 Mar 5. Neurobiol Aging. 2009. PMID: 18325635 Free PMC article.
-
A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro Evidence of Incorporation.Proteomes. 2021 May 24;9(2):24. doi: 10.3390/proteomes9020024. Proteomes. 2021. PMID: 34073856 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical